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Broadly neutralizing antibodies (bnAbs) directed
to the V2 apex of the HIV envelope (Env) trimer iso-
lated from individual HIV-infected donors potently
neutralize diverse HIV strains, but strategies for
designing immunogens to elicit bnAbs have not
been identified. Here, we compared four prototypes
(PG9, CH01, PGT145, and CAP256.VRC26.09) of
V2 apex bnAbs and showed that all recognized a
core epitope of basic V2 residues and the glycan-
N160. Two prototype bnAbs were derived from
VH-germlines that were 99% identical and used a
common germline D-gene encoded YYD-motif to
interact with the V2-epitope. We identified isolates
that were neutralized by inferred germline (iGL) ver-
sions of three of the prototype bnAbs. Soluble Env
derived from one of these isolates was shown to
form a well-ordered Env trimer that could serve as
an immunogen to initiate a V2-apex bnAb response.
These studies illustrate a strategy to transition from
panels of bnAbs to vaccine candidates.
INTRODUCTION
Much HIV vaccine research has recently begun to focus on how
to induce broadly neutralizing antibodies (bnAbs), because they
can neutralize multiple HIV strains and provide broad protection
in animal models. There is general agreement that the study of
bnAbs arising in natural infection is crucial in this endeavor (Bur-
ton and Mascola, 2015; Klein et al., 2013b). In particular, under-
standing how bnAbs from different individuals recognize the
same target on the virus promises to yield valuable information
for immunogen design and immunization strategies.
The surface HIV-1 envelope (Env) spike, a heterodimeric trimer
(gp120-gp41)3, is the sole target of bnAbs (Julien et al., 2013a;
Lyumkis et al., 2013; Pancera et al., 2014). Although, the EnvIspike employs a variety of mechanisms for immune evasion,
bnAbs effective against a wide spectrum of viruses develop
over time in natural infection (reviewed in Burton and Mascola,
2015). Thus far, several major target specificities of these bnAbs
have been reported and mapped to various sites on Env, which
include the CD4 binding site (CD4bs), the second variable loop
(V2) and the N160 glycan (V2 apex), the third variable loop (V3)
and glycan N332 (N332-V3 or high-mannose patch) of gp120,
the membrane proximal external region (MPER) of gp41, and
finally the gp120/41 interface region (reviewed in Ward and Wil-
son, 2015). These antibodies are highly potent and broadly
neutralizing against a diverse panel of HIV-1. Moreover, passive
transfer experiments in animal models have shown bnAbs to be
protective and therapeutic (reviewed in (Burton and Mascola,
2015; Klein et al., 2013b).
BnAbs typically take years to appear in natural HIV infection
in contrast to strain-specific anti-Env neutralizing Abs, which
emerge in the first few months of infection. Of the bnAbs, those
directed to the V2 apex emerge relatively early (Doria-Rose
et al., 2014; Moore et al., 2011; Wibmer et al., 2013). Further,
these bnAbs are elicited relatively frequently compared to
other bnAb specificities as shown in a number of studies
involving large cohorts of HIV infected donors (Georgiev et al.,
2013; Gray et al., 2011; Walker et al., 2010). In total, these find-
ings suggest that the V2 apex region could serve as an important
target for HIV vaccine development.
The V1V2 region is highly variable in terms of sequence,
length, and the extent of glycosylation (Zolla-Pazner and Car-
dozo, 2010). Due to sequence variation, antibody responses
to V1V2 tend to be strain specific, and furthermore, the loops
appear to sterically obstruct antibody access to the CD4bs on
the Env spike (Julien et al., 2013a; Pinter et al., 2004). Structur-
ally, the V1V2 region forms a four anti-parallel b stranded sheet
or a five b stranded barrel (McLellan et al., 2011; Pancera
et al., 2013; Pancera et al., 2014). V1V2 stabilizes the Env spike
forming the trimer apex (Julien et al., 2013a; Lyumkis et al., 2013;
Pancera et al., 2014). Further, the V1V2 region harbors the epi-
topes that are recognized by V2 apex directed bnAbs (Bon-
signori et al., 2011; Doria-Rose et al., 2014; Walker et al., 2011;
Walker et al., 2009). Indeed, among the major vulnerable targetmmunity 43, 959–973, November 17, 2015 ª2015 Elsevier Inc. 959
sites for bnAbs onHIVEnv, only Abs to theV2 apex display cross-
neutralizing activity with viruses from other groups of HIV-1
and simian immunodeficiency viruses (SIV), which infect gorillas
and chimpanzees, suggesting a cross-group and cross-species
conservation of this epitope (Barbian et al., 2015; Braibant et al.,
2013).
To date, four prototypes of V2 apex bnAbs (PG9, CH01,
PGT145, and CAP256.09) have been isolated from individual
HIV-1 infected donors (Bonsignori et al., 2011; Doria-Rose
et al., 2014;Walker et al., 2011; Walker et al., 2009). All recognize
the N-linked glycan at residue 160 (N160) to varying degrees and
a protein surface of the V2 domain of gp120. These antibodies
are either trimer-specific or trimer-preferring, frequently binding
with nM affinity to Env trimers but failing to show any significant
binding to monomeric gp120 (Doria-Rose et al., 2014; Sanders
et al., 2013; Sok et al., 2014; Walker et al., 2011; Walker et al.,
2009). Because these bnAbs appear early in infection, they
frequently possess relatively low levels of somatic mutation
compared to other bnAbs (Doria-Rose et al., 2014; Klein et al.,
2013a; Walker et al., 2011; Walker et al., 2009; West et al.,
2012). The antibodies are highly potent and broadly cross-reac-
tive and do not generally display autoreactivity. An important
characteristic of this group of antibodies is their extraordinarily
long CDRH3 loop (R24 amino acids), which helps them to pene-
trate the glycan shield on the Env spike trimer and access the
protein surface below (Julien et al., 2013b; McLellan et al.,
2011; Pejchal et al., 2010). The CDRH3 is anionic in nature and
possesses sulfated tyrosines, except the CH01 Ab prototype,
that appear to contribute to antibody binding (Pejchal et al.,
2010).
In this study, we compared the four prototype V2 apex bnAbs
in terms of the epitopes recognized and characteristics of
the Abs using a variety of approaches including mutagenesis
of the viral Env and antibody engineering. We highlighted com-
mon features of Env recognized by all the bnAb prototypes
and showed that two of the prototypes possessed some com-
mon features that were present in inferred germline versions of
the antibodies. We identified immunogens that bound to inferred
germline Abs and propose potential immunization strategies that
will facilitate HIV vaccine development.
RESULTS
The N-Linked Glycan at N160 and Lysine-Rich Strand C
Residues in the V2 Domain Form a Core Epitope for All
V2 Apex Prototype bnAbs
The trimeric nature of the V2 apex bnAb epitopes has hampered
their full structural characterization and determination of the
core epitope on the Env spike. The co-crystal structures of PG9
and PG16 antibodies with ZM109F.PB4 and CAP45.00.G3
V1V2 scaffolds shows that PG9 and PG16 CDRH3s primarily
interact with N-linked glycans at N160 and N156 or N173 and
positively charged amino acid residues in strand C (KKQK:
HXB2 numbering 168-171) of the V2 domain (Figure 1A;McLellan
et al., 2011; Pancera et al., 2013). Studies have shown that
neutralization mediated by V2 apex bnAbs is highly dependent
on the overall charge in strand C of the V2 domain (Doores and
Burton, 2010; Doria-Rose et al., 2012). Additionally, a recent lon-
gitudinal study of donor CAP256 (fromwhomCAP256-VRC26.09960 Immunity 43, 959–973, November 17, 2015 ª2015 Elsevier Inc.Ab was isolated, which we refer here as CAP256.09) yielded a
neutralization escape virus with mutation at the K169 residue of
strand C (Figure 1B) (Doria-Rose et al., 2014). In this study, we
isolated viruses from two IAVI protocol G HIV-infected donors,
64 and 584, from whom PG9 and PGT145 bnAbs were isolated,
respectively (Walker et al., 2011; Walker et al., 2009). We found
that these viruses were resistant to neutralization by PG9 and
PGT145 bnAbs (data not shown), indicative of viral escape. The
sequence analysis of these escape variants revealed mutations
at the K169 and K171 strand C residues (Figure 1B), again sug-
gestive of antibody selection pressure in this region (Moore
et al., 2011; Moore et al., 2013).
Based on these observations, we generated a series of vari-
ants of the 16055.2.3 Env by substitution of residues in the strand
C region and elimination of the glycans at N156 and N160. The
Env was chosen because it derives from a subtype C virus that
is sensitive to neutralization by all four V2 apex bnAb prototypes.
The type of substitutions made were chosen on the basis of
amino acid variability around the strand C residues in different
HIV isolates and included the escape mutations at residues
K169T and K171E found in the PG9 donor escape virus
(Figure 1A; Figure S1, Table S1). We tested two Abs from each
V2 apex bnAb prototype against the Env pseudovirus variants
in the standard TZM-bl cell neutralization assay (Seaman et al.,
2010). The results revealed that all of the V2 apex antibody pro-
totypes preferred positively charged residues at positions 168,
169, and 171 (HXB2 numbering). Apart from the CAP256.09 Ab
prototype, which seemed to be more dependent on K169, a
combination of two substitutions was required to completely
abrogate neutralizing activity, suggesting avid antibody binding
to the epitope (Table S1). Further, the N160 glycan was obliga-
tory for all V2 apex bnAbs except the CAP256.09 prototype,
which showed a partial dependence on N160, in agreement
with earlier findings (Doores and Burton, 2010; Doria-Rose
et al., 2014; Walker et al., 2011; Walker et al., 2009). To rule
out any virus envelope-specific bias, we tested the most critical
mutations on a subtype A HIV envelope, BG505.Env.C2 and
found a similar trend (Table S1). Overall, we observed that all
of the V2 apex bnAb prototypes were sensitive to mutations at
glycan N160 and four strand C residues with subtle differences
in terms of their epitope requirement, K169 being the common
requisite for all prototypes (Figure 1C).
The Glycan at N160 Is Crucial for All V2 Apex bnAbs, but
There Are Differences in Fine Specificity for Glycan
Recognition
In order to investigate the nature of glycans recognized by the
V2 apex bnAbs, we employed three approaches. First, we gener-
ated knockouts of the glycans at N156 and N160 in the
BG505.Env.C2 SOSIP.664 soluble Env trimer to complement
those previously generated in the 16055.2.3 virus and shown in
Figure 1. We tested two Abs from each V2 apex bnAb prototype
against the Env trimer variants for ELISA binding. Consistent with
the 16055.2.3 virus neutralization results, binding of the V2 apex
bnAbswas highly dependent on the N160 glycan (Figures 2A and
2B, Table S2). The exception was the CAP256.09 Ab prototype,
whose binding showed partial dependence on N160. Second,
we produced the 16055.2.3 virus and soluble SOSIP.664 Env
trimer in the presence of the glycosidase inhibitors kifunensine
Figure 1. Epitope Recognition by V2 Apex bnAbs
(A) PG9 CDRH3 interaction with glycans and strand B and C of the V1V2 domain presented on a scaffold shown as a ribbon representation (modified from
McLellan et al., 2011). PG9CDRH3-interacting amino acid residues are shown in orange with side chains as sticks. The V2 glycans N160 andN173 are depicted in
red, and the four key residues from the lysine-rich strand C are shown in blue with side chains as sticks.
(B) Amino acid sequence alignment of strands B and C of isolate 16055.2.3, BG505.Env.C2, IAVI donor 64 PG9 antibody escape virus, IAVI donor 584 PGT145
antibody escape virus, and donor CAP256 CAP256.09 antibody escape virus (HXB2 numbering: 156-177). The sequences were aligned with clustalX in the
BioEdit program. The N-linked glycan sites N156 and N160 are shown in red, the four amino acids in the lysine rich region on strand C are shown in blue, and the
escape mutations at position 169 and 171 in the donor escape viruses are highlighted in pink.
(C) Graphic representation of the epitopes for four (PG9, CH01, PGT145, and CAP256.09) V2 apex bnAb prototypes. Each cartoon represents the cysteine-linked
V1V2 loops (HXB2: 126-196), highlighting the core epitope for all the V2 apex bnAb prototypes. The epitope includes the glycans N156, N160, and four strand C
amino acid residues. The size of each amino acid letter is proportional to the dependence on that residue for neutralization.
See also Figure S1 and Table S1.(ER a - mannosidase I inhibitor) and swainsonine (Golgi a - man-
nosidase II inhibitor). Kifunensine and swainsonine are ex-
pected to modify glycan processing of sugars on the Env trimer
to yield mostly high mannose (Man9GlcNAc2) and hybrid-type
glycanswith aMan5GlcNAc2 core, respectively (Doores andBur-
ton, 2010). The results revealed that neutralization by all the V2
apex bnAbs was generally sensitive to kifunensine treatment in
an isolate and context-dependent manner as observed previ-
ously (Doores and Burton, 2010; Doria-Rose et al., 2014; Walker
et al., 2011). Swainsonine treatment hadminimal effects (Figures
2A and 2B, Table S2). These results indicated that V2 apex
bnAbs were possibly unable to tolerate extra high-mannose
sugars (Man9GlcNAc2) at glycan N160. Third, we assessed the
reactivity of the bnAbs to different types of glycans on glycan
microarrays (Table S3). Antibodies from PG9 and CAP256.09
Ab prototypes showed reactivity to glycans, whereas PGT145
and CH01 Ab prototypes did not display any binding. PG9
and CAP256.09 Ab prototypes showed reactivity to a variety of
diverse glycans with terminally linked a-2-3 or a-2-6 sialic acidIresidues (Figure 2C, Table S3). Notably, PG9 Ab bound preferen-
tially to glycans with a a-2-3 linked sialic acid, whereas PG16
preferred a a-2-6 linkage, consistent with previous findings (Pan-
cera et al., 2013). Overall, the results reveal that glycan at posi-
tion N160 is important for all V2 apex bnAbs and two of the anti-
body prototypes PG9 and CAP256.09 can bind diverse glycan
types with sialic acid as the terminal sugar.
PG9/PG16 and CAP256.09 Are Derived from Similar VH
Germline-Gene Families and Contain a Conserved YYD
Motif in CDRH3 that Interacts with the V2 Domain
In order to identify common features used by different V2 apex
bnAbs, we compared the closest inferred variable heavy- (VH)
and variable light- (VL) chain germline sequences (predicted by
the ImMunoGeneTics [IMGT] human immunoglobulin G [IgG]
germline database, http://www.imgt.org) (Brochet et al., 2008),
from each prototype. We found that PG9/PG16 and CAP256.09
antibodies were derived from different VH-germline gene fam-
ilies, but these families shared 99% sequence identity at themmunity 43, 959–973, November 17, 2015 ª2015 Elsevier Inc. 961
(legend on next page)
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aminoacid level asdepicted in Figure 3A (FigureS2A). In addition,
the D-gene usage for these two Ab prototypes was identical (Fig-
ure 3A, Table S4). The CH01 and PGT145 Ab prototypes were
derived from different VH gene families with many differences
in amino acid sequence (Figure 3A, Table S4). The VL germline
sequences for all the Ab prototypes were derived from diverse
gene families (Table S4). The extent of somatic mutation for
different Ab prototypes ranged from 14% to 17% in VH and
from 9% to 17% in VL chains at nucleotide level (Table S4). Com-
parisonofCDRH3sequencesshowedconservationof a tyrosine-
tyrosine-aspartic acid [YYD]motif in PG9, PG16, andCAP256.09
Abs (Figure 3B). The YYD motif in these antibodies originated
from the germlineD-geneand remainedunchanged in themature
antibody (Brochet et al., 2008; Doria-Rose et al., 2014; Walker
et al., 2009). We created single amino acid substitutions in PG9
and PG16 antibodies in the YYD motif and tested for the ability
of the mutant antibodies to neutralize four viruses with varying
degrees of neutralization sensitivity. The results showed partial
or complete loss of antibody neutralizing activity (Figure 3C).
Substitution of the D112.8 (IMGT numbering) residue showed
the most profound effect on antibody activity. A similar result
was observed on the ELISA binding capacity of these antibody
variants to recombinant gp120 proteins when this could be
assessed (Figure 3D). Overall, these results suggest that PG9,
PG16, and CAP256.09 Abs were derived from similar VH genes
andpossessamotif in theirCDRH3encodedbyacommongerm-
line-D region. PG9 Ab structural studies have shown this motif
(McLellan et al., 2011; Pancera et al., 2013) to recognize the basic
strand C residues in the V2 domain; however, it remains to be
seenwhether CAP256.09 Ab structurally uses a similar or distinct
mode for epitope recognition.
Inferred Germline (iGL) Versions of V2 Apex bnAbs Can
Neutralize a Number of Viruses
Several studies indicate the importance of a long CDRH3 for
binding of the V2 apex bnAbs to Env and for neutralization.
Indeed, the PG9 and PG16 antibody CDRH3s are thought to
form a subdomain (‘‘hammerhead’’) that permits these anti-
bodies to penetrate through the glycan shield to reach the pro-
tein surface (McLellan et al., 2011; Pancera et al., 2010; Pejchal
et al., 2010). Further, the ability to exchange the CDRH3s of PG9
and PG16 with exchange of neutralization specificity has previ-
ously been shown (Pancera et al., 2010; Pejchal et al., 2010).
As one approach to investigating the role of CDRH3 and other
antibody sequence elements in V2 apex bnAbs in general, we
generated a series of VH and/or VL chain reverted inferred germ-
line (iGL) antibodies according to the schematic shown in Fig-
ure 4A in which the mature CDRH3 and CDRL3 were retained.Figure 2. Glycan Specificity of V2 Apex bnAbs
(A) V2 apex bnAb neutralization of Env variants displaying differing glycan compo
prototype were tested for neutralization against 16055.2.3 wild-type (WT), N156K
inhibitors kifunensine (Kif) and swainsonine (Swain).
(B) The four V2 apex bnAb prototypes were tested in ELISA binding to Galla
glycovariants. The gp120-gp41 glycan dependent Ab PGT151, the CD4bs Ab VR
(C) Reactivity of V2 apex bnAbs with glycans on a glycan microarray. The V2 ap
Relative Fluorescence Units (RFU) and the error bars represent the average perce
indicated. The glycan dependent antibody PGT151 was used as control.
See also Tables S2 and S3.
IUsing the mature CDRH3s in the reverted Abs remains one
of the limitations of this study. These Abs, referred to as ‘‘iGL
Abs,’’ were generated by replacing the VH or VL gene segments
in the corresponding mature (Mat) antibodies with their closest
iGL sequence (IMGT). The antibodies were tested against a
panel of 18 tier 2 viruses from different HIV clades (Table S5).
We found that PG9, CH01, and CAP256.09 VH-VL iGL Ab proto-
types exhibited neutralization of a number of viruses, whereas
PGT145 did not. There was a rough inverse correlation between
the number of somatic mutations in the VH and VL regions and
neutralization IC50 but with considerable variation so that potent
neutralization was seen on occasion with no or a limited number
of mutations, especially for the CH01 and CAP256.09 Abs (Fig-
ures 4B and 4C) (Table S5). Because the iGL Abs have mature
CDRH3s, Figure 4C illustrates that the breadth of PGT145
neutralization was particularly dependent on somatic mutations
in the VH and VL chains. The inferred GL Abs showed similar
glycan dependence in virus neutralization as compared to their
mature versions (Table S6) and did not display autoreactivity
(Figure S4).
To gain more insight about the role of somatic mutations in the
PGT145 Ab prototype, we compared the PGT143 and PGT145
mature VH sequences with their germline sequence and identi-
fied a substantial number of somatic mutations in the CDRH1,
CDRH2, and FR3 regions that could be important for antibody
neutralization (Figure S3A). To evaluate the role of these muta-
tions, we generated PGT145 antibody variants by independently
replacing the three regions described in the mature VH with the
corresponding germline sequence, paired with mature VL, and
tested the resulting antibodies for neutralization. The results re-
vealed a strong dependence of PGT145 antibody activity on
the CDRH2 region, and a similar effect was confirmed for
PGT143 (Figure S3B). Overall, these results suggest that the
PGT145 Abs represent a discrete group of V2 apex bnAbs.
Neutralization of Isolates by iGL Versions of PG9 and
CAP256.09 Is Not Due to the CDRH3 Alone
The iGL-reverted versions of PG9 and CH01 Abs neutralized only
a fraction of the viruses that were neutralized by their respective
mature Abs, which highlights the significance of somatic muta-
tions in the variable HC and LC regions for Ab function. However,
the CAP256.09 iGL-reverted Ab, albeit less potently, neutralized
all the viruses that were sensitive to itsmature version in the panel
used, implying that the neutralization activity could be almost
entirely mediated by CDRH3. To investigate the role of CDRH3
and the VH germline gene segment in V2 apex bnAb neutraliza-
tion, we employed antibody engineering to generate a panel of
PG9 and CAP256.09 iGL Ab variants with diverse VH-GL genessition in the context of the 16055.2.3 isolate. Two Abs from each V2 apex bnAb
, N160K glycan variants, and viruses produced in the presence of glycosidase
nthus Nivalis Lectin (GNL)-purified BG505.Env.C2.SOSIP.664 soluble trimer
C01, and a Dengue Ab (DEN3) were used as controls.
ex bnAbs were tested for reactivity on a glycan array. The data are shown as
ntage error for all data points reported. The symbol for each monosaccharide is
mmunity 43, 959–973, November 17, 2015 ª2015 Elsevier Inc. 963
Figure 3. Variable (V), Diversity (D), and Joining (J) Gene Families Encoding V2 Apex bnAbs and Conservation of the YYD Motif in PG9 and
CAP256.09 Prototype Abs
(A) Representation based on the amino acid sequence alignment of the inferred germline-encoding heavy-chain variable regions (VH). The V, D, and J gene usage
for various V2 apex bnAb prototypes (denoted on the right) is listed in the boxes. The V-gene sequence alignment shows that PG9 and CAP256.09 Ab prototypes,
derived from different gene families share 99% sequence similarity at amino acid level (shown in red) and use same germline D-gene. Different gene families
encode the J-genes for each of the Ab prototypes. Abs possess (N)-nucleotide insertions of variable lengths at V-D and D-J junctions in the CDRH3.
(B) Sequence alignment of CDRH3 sequences of V2 apex bnAbs shows conservation of the YYDmotif (underlined bold) in PG9, PG16, and CAP256.09 antibody
prototypes. IMGT numbering is shown.
(legend continued on next page)
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and a common CDRH3 from either PG9 or CAP256.09 that are
termed ‘‘inferred germline-VH Ab variants’’ (Figure 5A). The
choice of VH GL genes was based on the gene families used
by HIV bnAbs targeting different sites on Env (Bonsignori et al.,
2011; Gorny et al., 2005; Walker et al., 2011; Walker et al.,
2009; West et al., 2012). We paired these VH iGL variants with
the respective Ab (PG9 orCAP256.09) light-chain iGLs and tested
them against ZM233M.PB6 as a prototype virus because it was
effectively neutralized by both iGL Abs. We observed a complete
loss of neutralization for PG9 VH-GL Ab variants, whereas some
of the CAP256.09 VH-GL Ab variants neutralized the virus with
very low potency (Figure 5B). The results suggest that a combina-
tion of VH germline and CDRH3 is required for the corresponding
germline antibody activity.
To further validate this finding, we transplanted the CDRH3
regions from mature PG9 and CAP256.09 antibodies on to
the framework of different V2 apex mature antibodies (2909,
PGT145, PG9, or CAP256.09) (Doria-Rose et al., 2014; Gorny
et al., 2005; Walker et al., 2011; Walker et al., 2009). The basis
for using these antibodies as scaffolds for PG9 and CAP256.09
CDRH3 was to partially retain the configuration of antibody
structure that would naturally align with the quaternary V2
epitope. Furthermore, these antibodies use different somatic
mutation patterns in their VH and VL chains that, in concert
with the respective CDRH3, define their mode of neutralization,
and thus can provide a means to assess the precise role of
CDRH3. For example, the antibody 2909 can only neutralize
viruses that lack a glycan at the N160 position (Gorny et al.,
2005). Hence neutralization of any virus that has a glycan at
N160 by antibody 2909 in which the native CDRH3 has been re-
placed with that from PG9 or CAP256.09 can be attributed to the
transplanted CDRH3. A panel of transplanted antibodies with
PG9 and CAP256.09 CDRH3s showed no neutralizing activity
against a panel of viruses with a single exception (Table S7).
Together, these results suggest that the VH germline genes in
PG9 and CAP256.09 iGL Abs play a vital role in neutralization
of sensitive viruses and their ability to neutralize these viruses
is not a function of CDRH3 alone.
Common Patterns of Somatic Mutation in PG9, PG16,
and CAP256.09 Contribute to Broad Neutralization
The fact that two of the V2 apex bnAb prototypes, PG9, PG16,
and CAP256.09, are derived from almost identical VH germline
precursor gene sequences at the amino acid level implies the
selection of VH structural features that favor interaction with
a V2 antigenic structure. These features might be present in
the germline configurations of the antibodies and/or emerge
during affinity maturation. To investigate, we compared the so-
matic mutation patterns in the VH genes of PG9, PG16, and
CAP256.09 by aligning the mature HC sequences with their
respective iGL sequences. The alignment revealed eight com-
mon positions in VH at which all three bnAbs had mutations
away from germline. For three of these positions, namely Y67,(C) The effects of substitutions in the YYDmotif amino acid residues in PG9 and PG
PG9 and PG16 Abs and variant antibodies against a 4-virus panel are represent
(D) Binding of WT PG9 and PG16 Abs and their variants to recombinant GNL-puri
CD4bs (b6, b12 and PGV04), and Dengue (DEN3) were used as control mAbs.
See also Figure S2 and Table S4.
IK72, and Y103 in the FR3 region, common mutations, to yield
H67, W72, and F103, were noted in all three antibodies (Fig-
ure 6A). To confirm the role of somatic mutation in neutralization,
we incorporated the mutations observed in PG9 at the eight
positions described into the PG9 heavy-chain iGL, ‘‘PG9 VH
iGL-modified Ab,’’ and found up to a 46-fold improvement in
IC50 neutralization for four viruses that PG9 antibody neutralized
as an iGL Ab (Figure 6C, Figure S5). In addition, the VH iGL-modi-
fied PG9 Ab gained 50% (IC50) neutralizing activity against
two new viruses (CAP45.00.G3 and CRF02_AG_250), suggest-
ing that the common sites of somatic mutation in VH in PG9,
PG16, and CAP256.09 Abs were important for their function.
Because PG9 LC somatic mutations were essential for anti-
body-neutralizing activity (Figures 4B and 4C), we hypothesized
that combining the somatic mutations in VH with VL mutations
might have a complementary effect, especially residues E37,
S38, and D56 that are critical for glycan recognition (McLellan
et al., 2011; Pancera et al., 2013). Hence, we generated a PG9
iGL variant ‘‘PG9 VH-VL iGL-modified Ab’’ in which eight muta-
tions were introduced into both the HC and the LC of iGL PG9
(Figure 6B). Because CAP256.09 was encoded by a different
LC germline gene, it was not investigated. Glycan reactivity
was partially restored in the PG9 VH-VL iGL-modified Ab variant,
as determined by glycan microarray (Figure S5), and the variant
neutralized 89% (16/18) of virus isolates, albeit less potently than
the mature PG9 antibody, in spite of having only about half the
level of SHM of the mature antibody (Figure 6C, Figure S5).
The somatic mutations in VH and VL chains of PG9 are depicted
as surface rendering in Figure 6D. The location of somatic muta-
tions in the VH and VL chains suggests that the gain of antibody
function can be attributed to either a stabilizing effect or to direct
interaction with the V2 epitope, possibly with glycans not fully
described in the scaffold structures. Overall, the findings sug-
gest that V2 apex bnAbs, particularly PG9 and CAP256.09 Ab
prototypes, use similar antigen-driven developmental pathways
to accumulate somatic mutations.
The CRF02_AG_250 Virus Is Neutralized by 3 iGL
Prototype bnAbs and a Well-Ordered Trimer Env from
This Isolate Can Be Constructed That Is a Potential
Immunogen
In this study, we identified 5 HIV isolates across different HIV
clades that are neutralized by iGL Abs from two or more V2
apex bnAb prototypes (Table S5). Of the five HIV isolates,
one isolate, ZM233M.PB6, has been previously shown to
be sensitive to PG9 and CH01 iGL Ab prototypes (Bonsignori
et al., 2011; Pancera et al., 2010). Three of the isolates,
CRF02_AG_250 (subtype AG), ZM233M.PB6 (subtype C), and
C1080.c03 (subtype AE), were neutralized by three of the four
iGL Ab prototypes (PG9, CH01, and CAP256.09) and the
neutralization curves are presented for CRF02_AG_250 virus
(Figure 7A, left). These results suggest that the CRF02_AG_
250, ZM233M.PB6, and C1080.c03 isolates presented the V216 Abs on neutralization of viruses. The IC50 neutralization titers of mature (WT)
ed as bars.
fied gp120 proteins by ELISA. Antibodies to the high mannose patch (PGT128),
mmunity 43, 959–973, November 17, 2015 ª2015 Elsevier Inc. 965
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Figure 5. Neutralization of ZM233M.PB6 by PG9 and CAP256.09 Heavy-Chain Inferred Germline Antibody Variants
(A) Schematic representation of PG9 and CAP256.09 inferred germline-VH Ab variants. The PG9 or CAP256.09 VH-germline gene was replaced by germline-VH
encoding sequences from diverse HIV-1 specific Abs. The selected germline genes are used by envelope specific bnAbs that include IGHV1-2-02 (CD4bs),
IGHV1-8-02, IGHV3-15-01, IGHV3-20-01, IGHV3-43-01 (V2 apex), IGHV4-59-01 (N332-V3), andIGHV5-51-01 (V3).
(B) Neutralization of ZM233M.PB6 virus by PG9 and CAP256.09 iGL variant antibodies in which the VH germline has been substituted as in (A) above.
See also Table S7.epitope differently as compared to other isolates that are
equivalently sensitive to neutralization by the mature V2 apex
bnAbs but were not neutralized by the corresponding iGL Abs
(Table S5). The unusual sensitivity of these isolates to neutrali-
zation by iGL Abs from different V2 apex Ab prototypes sug-
gests that the corresponding Env trimers might be useful in
priming appropriate B cell responses. Accordingly, we decided
to investigate a well-ordered recombinant Env trimer from
isolate CRF02_AG_250.
We constructed a SOSIP.664 Env trimer from the CRF02_
AG_250 sequence and purified this protein with a trimer-specific
Ab PGT145 affinity column to enrich for a well-ordered Env
trimer population. PGT145 antibody is a strictly trimer-specific
antibody and enriches for highly homogeneous and consistently
folded well-ordered native-like envelope trimers (Sanders et al.,
2013). ELISAbinding titrations revealed that the iGLAbsexhibited
a strong reactivity with the CRF02_AG_250 SOSIP.664 trimer
(Figure 7A, middle). In addition, the CRF02_AG_250 SOSIP.664Figure 4. Neutralization Breadth and Potency of Mature, Chimeric, and
(A) A schematic representation of chimeric and inferred germline (iGL) reverted
(gray), the variable heavy (VH) chain (red), and variable light (VL) chain (green). T
chains are shown at the end of each variable region. The VH and VL genes are fu
with ImMunoGeneTics (IMGT) numbering. To generate the VH or VL regions in iGL
the IMGT human IgG germline database (Brochet et al., 2008). The CDRH3 and
(B) Association of IC50 neutralization titers with number of somatic mutations in V
(C) Neutralization breadth of Mat, chimeric and iGL reverted V2 apex bnAbs. The
shown for Mat and chimeric Abs. For the less potent iGL Abs, neutralization is s
See also Figures S3 and S4 and Tables S5 and S6.
Itrimer displayed strong binding to the CAP256-derived less
mutated Ab intermediates, CAP256.I1 and CAP256.I2, and an in-
ferred unmutated common ancestor Ab (CAP256 UCA) that was
identified by 454 next-generation sequencing (NGS) from the
CAP256 donor and is believed to have initiated the CAP256 Ab
lineage (Doria-Rose et al., 2014). Remarkably, CRF02_AG_250
envelope showed notable similarities to CAP256 superinfecting
donor virus (CAP256.SU), including amino acid sequence simi-
larity in the strand B and C of V2 loop and the neutralization
sensitivity pattern to various members of the CAP256 family of
Abs (Figures S6 and S7). We also assessed the binding of iGL
Abs to monomeric gp120 from the CRF02_AG_250 isolate;
with the exception of some weak binding by mature PG9 (and
its chimeric variants), the mature and reverted iGL Abs from all
four antibody prototypes failed to bind the gp120 protein (Fig-
ure 7A, right). Finally, to evaluate the antigenic profile of the
CRF02_AG_250 SOSIP.664 trimer, we tested its binding to a
range of neutralizing and non-neutralizing Abs (Figure S7). TheInferred Germline Reverted V2 Apex bnAbs
antibodies. The mature antibody, referred to as ‘‘Mat’’ shows constant region
he third complementarity determining regions of VH (CDRH3) and VL (CDRL3)
rther divided into framework regions (FR1-3) and other CDRs (CDR1-2) shown
, we replaced Abs in with their closest inferred germline sequence predicted by
CDRL3 from the Mat antibodies were retained in the reverted iGL Abs.
H and VL for the four prototype Abs, PG9, CH01, CAP256.09, and PGT145.
number of viruses in an 18-virus panel neutralized with an IC50 < 10 mg/ml is
cored as positive with IC50 < 100 mg/ml.
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Figure 6. Comparison of Mutations in PG9 and CAP256.09 Contributing to Broad Neutralization
(A and B) Sequence alignment of mature heavy- (A) and light- (B) chain sequences of PG9, PG16, and CAP256.09 antibodies with their corresponding inferred
germline (iGL) encoding sequences. Each VH and VL gene sequence is divided into FR1-3 and CDR1-2 with junctions underlined. (A) Common positions at which
somatic mutations occur in the mature HC of PG9, PG16, and CAP256.09 Abs are highlighted in cyan, common mutations shown in red. (B) Common somatic
mutations at eight positions in mature PG9 and PG16 VL are highlighted in cyan. E37 in PG9, which is (D) in PG16, essential for glycan recognition (McLellan et al.,
2011; Pancera et al., 2013) is included.
(C) The VH or VH-VL iGL-modified PG9 Ab variants were tested against the 18-virus panel and the median IC50 neutralization titers are shown for each.
(D) Ribbon representation of PG9 antibody in complex with a ZM109F V1V2 loop (green) scaffold (modified from McLellan et al., 2011). The glycans at N160 and
N173 positions (red; represented as sticks) and strand C residues (blue) in V2 domain are labeled. The PG9 variable heavy- (cyan) and light- (aqua) chains illustrate
common positions (shown as surface rendering) at which somatic mutations occur in PG9, PG16, and CAP256.09 HC (denoted by residues in black) and PG9 and
PG16 LC (denoted by residues in red).
See also Figure S5.CRF02_AG_250 trimer showed little or no reactivity with non-
neutralizing Abs but robust binding to neutralizing Abs consistent
with a well-ordered trimer configuration (Sanders et al., 2013).
The binding pattern of Abs to the SOSIP.664 trimer was highly
correlated with virus neutralization (Figure S7) and overall the
data suggest that the trimer is a promising immunogen to prime
V2 apex bnAb responses.
DISCUSSION
The interaction of bnAbs with Env trimer offers valuable informa-
tion on which to base rational HIV vaccine design strategies.968 Immunity 43, 959–973, November 17, 2015 ª2015 Elsevier Inc.Study of multiple mAbs isolated from several infected donors
provides an opportunity to gain a better understanding of the re-
quirements for recognition of a given broadly neutralizing region
and should lead to more reliable immunogen design (Jardine
et al., 2013; Zhou et al., 2013). In essence, a better appreciation
is gained of the features in the immunogen and the bnAb that are
most critical for neutralization are obtained allowing for greater
precision in immunogen design. The first of the new generation
of more potent HIV bnAbs targeted an epitope associated with
the V2 region of the Env trimer (Walker et al., 2009) and since
then it has become clear that this region is a major target
for bnAbs in natural HIV infection. It is estimated that roughly
Figure 7. The CRF02_AG_250 Virus Is Neutralized by Three iGL Prototype bnAbs and Forms Well-Ordered Recombinant Env Trimers
V2 apex bnAb neutralization of CRF02_AG_250 virus and binding to the corresponding SOSIP.664 and gp120 proteins. Left column shows that the mature (Mat),
VH or VL reverted chimeric and VH-VL iGL antibodies from each Ab prototype, an inferred unmutated common ancestor (CAP256 UCA), and two intermediate
(CAP256.I1 and CAP256.I2) Abs derived from the CAP256 donor, were tested for neutralization against the CRF02_AG_250 virus. The neutralization curves show
the activity of Abs, Mat (filled diamond), VH or VL reverted chimeras (half-filled diamond), VH-VL iGL (empty diamond). Middle column shows that Abs were
assessed for binding to the PGT145 antibody affinity purified soluble trimeric Env form (SOSIP.664) of CRF02_AG_250 by ELISA. Right column shows that Abs
were further tested for binding to the GNL-affinity purified monomeric gp120 protein corresponding to CRF02_AG_250 envelope, by ELISA. Antibodies, PGT128,
PGT151, and DEN3 were used as controls.
See also Figures S6 and S7.21%–42% of bnAbs in several cohorts are reactive with the
region (Georgiev et al., 2013; Gray et al., 2011; Walker et al.,
2010) and several bnAbs have been isolated (Bonsignori
et al., 2011; Doria-Rose et al., 2014; Sok et al., 2014; WalkerIet al., 2011; Walker et al., 2009). In this study, we have compared
bnAbs to the region, determined common features of Abs andAb
recognition, and designed immunogens that might favor trig-
gering of B cell responses to the region.mmunity 43, 959–973, November 17, 2015 ª2015 Elsevier Inc. 969
Structural studies have shown that the V2 bnAbs target a qua-
ternary epitope at the apex of the Env trimer, and we refer to
them here as ‘‘V2 apex bnAbs.’’ We show that all four prototypes
of V2 apex bnAbs bind to a core protein epitope involving the
lysine-rich beta-strand C in the V2 domain, with Lys169 being
the common requirement, and an N-linked glycan at position
160. Interestingly, within a relatively conserved region of V2
domain (HXB2: 155-183 [http://www.hiv.lanl.gov]), the Lys169
and Lys171 residues in strand C, which form the core epitope
for V2 apex bnAbs, are themost variable residues in viral isolates
across diverse HIV-1 subtypes (Figure S1). Thus the V2 apex
bnAbs have acquired the ability to recognize, within certain
boundaries, variation in the core epitope. Presumably, a suc-
cessful immunization regime therefore would need to induce
this ability, possibly by use of multiple immunogens with differing
core protein epitopes.
Access to the core V2 protein epitope is reached by pene-
trating between glycans, notably glycans at N160 and N156.
Structural and functional studies have previously shown that
PG9 and PG16 antibodies make extensive contacts with Man5-
GlcNAc2 at N160 and a hybrid-type glycan at N156 or N173
positions (Doores and Burton, 2010; McLellan et al., 2011; Pan-
cera et al., 2013; Walker et al., 2009). The PG9 and PG16 clonal
variants have been shown to subtly differ in terms of their prefer-
ence for the terminal glycosidic linkages (Pancera et al., 2013).
The two prototypes of V2 apex bnAbs, PG9, and CAP256.09
appear to recognize a large spectrum of glycans with terminally
linked a-2-3 or a-2-6 sialic acid residues. These findings suggest
that these antibodies have evolved to recognize diverse sugars
to counter the glycan diversity, which the virus uses for immune
evasion.
The structural feature of the V2 apex bnAbs that allows pene-
tration of the glycan shield to reach the core protein epitope is an
extraordinarily long CDRH3 loop (McLellan et al., 2011; Pejchal
et al., 2010). Therefore it might have been anticipated that the
inferred germline antibodies (iGL) from three V2 apex bnAb pro-
totypes (PG9, CAP256.09, and CH01) that maintain the CDRH3
from the mature antibody are able to neutralize some viruses,
consistent with the importance of the CDRH3 for antibody ac-
tivity. In contrast, despite having a long CDRH3, PGT145 was
shown to be also dependent on CDRH2 and the VL chain. Over-
all, it appears that the PGT145 prototype Ab is distinct from the
other 3 Ab prototypes. Further, the three V2 apex bnAb pro-
totypes show higher levels of somatic mutation in their HCs
as compared to LCs, whereas PGT145 shows similar levels in
both chains (Table S4). In general, it seems the induction of
PGT145-like Abs, which includes some of the most potent V2
apex bnAbs (Sok et al., 2014; Walker et al., 2011), might require
immunization strategies distinct from those for the other three
prototypes.
Within the group of three prototype bnAbs described above,
PG9 and CAP256.09 show many notable similarities. The two
prototypes are derived from distinct VH germline gene families
but with almost identical amino acid sequences. Inferred germ-
line versions (iGL) of these Abs do neutralize a number of iso-
lates. Formally, the occurrence of these VH genes could have
been random or due to selection by a V2 apex structure because
of the strong neutralization dependence on CDRH3, which is
not encoded by the VH gene. Antibody engineering experiments970 Immunity 43, 959–973, November 17, 2015 ª2015 Elsevier Inc.strongly supported the selection theory because replacement of
the VH germline gene in iGL versions of PG9 andCAP256.09with
other VH genes was not associated with neutralizing activity.
Presumably a B cell receptor (BCR) shape associated with this
V gene favorably interacts with a part of the V2 apex epitope.
Epitope-specific VH germline gene preference has been previ-
ously observed for other HIV envelope target sites (Jardine
et al., 2013; Klein et al., 2013a).
As well as having a 99% amino acid identical germline VH
gene, PG9 and CAP256.09 also both retain a conserved tri-
peptide motif (YYD) in their CDRH3, which originates from the
same germline D-gene and remains unmodified in the mature
antibodies. We observed this motif to be essential for antibody
neutralization and it has been shown previously to be critical
for interaction with the Lys-rich strand C residues (McLellan
et al., 2011; Pancera et al., 2013). Therefore overall, it appears
that PG9 and CAP256.09-like responses could be initiated
when the appropriate V gene in combination with a long
CDRH3 incorporating the appropriate D gene is triggered.
Following triggering, there is a suggestion from study of PG9
and CAP256.09 of a common maturation pathway as observed
in a number of somatic mutations at common positions in
both VH genes. A rationally designed immunogen employed
following triggering might seek to shepherd maturation along
this pathway.
Considering the initiation of a V2 apex bnAb response, we
showed here that CRF02_AG_250, a subtype AG isolate, is
recognized by 3 V2 apex iGL Ab prototypes. Additionally, in
this study, we identified a number of envelopes that displayed
an antigenic profile similar to that from the CRF02_AG_250
isolate (Table S3), including one isolate that was shown to be
neutralized by PG9 and CH01 iGL Ab (Bonsignori et al., 2011;
Pancera et al., 2010). The CRF02_AG_250 isolate showed a
few noteworthy similarities with the CAP256.SU envelope that
presumably triggered the CAP256 V2 apex Ab lineage. The
Env trimer molecule (SOSIP.664) from the CRF02_AG_250
isolate could be constructed and purified with the Env trimer-
specific Ab, PGT145, with a protein yield that is comparable to
BG505.Env.C2 SOSIP.664 trimer (Sanders et al., 2013). A solu-
ble Env trimer derived from the CRF02_AG_250 isolate showed
a favorable antigenic profile in that it displayed strong reactivity
with bnAbs but did not bind to non-neutralizing antibodies
directed to various antigenic sites on envelope. These findings
suggest that CRF02_AG_250 and related trimer phenotypes
might be used as a germline targeting immunogen to trigger V2
apex bnAbs.
Overall, the results suggest a potential strategy for the elicita-
tion of bnAbs, particularly of the PG9, CAP256.09 type. First, the
immune system should be primed with a motif-targeting mole-
cule that can engage B cells with the YYD motif in the CDRH3.
Interestingly, the YYD motif can originate independently from
four major germline D-genes (3-3, 3-9, 3-16, and 3-22) (Brochet
et al., 2008) and hence should constitute a significant precursor
B cell pool. Ideally, one would couple selection of the YYD motif
with that for a long HCDR3. This might be accomplished using
a conformationally constrained molecule such as a trimeric V2
scaffold or trimeric V2 apex structure presented on a virus like
particle (VLP) that is capable of enriching YYD motif possessing
B cells. Alternatively, the CRF02_AG_250-like trimers might be
directly used to prime the YYD motif-bearing long CDRH3 pre-
cursor B cell. The next step would involve boosting with trimer
variants that can specifically enrich for somatic mutations in
VH and VL chain variable regions. Such boosting might involve
cocktail or sequential immunization with Env variants (Bonsignori
et al., 2011; Pancera et al., 2010; Wang et al., 2015). The combi-
nation of designed immunogens and immunization strategies
based on the type of data presented here together with empirical
evaluation of immunogens in animal systems, particularly those
expressing human antibody repertoires such as humanized or
knockin mice (Jardine et al., 2015; Lee et al., 2014), is most likely
to be successful in inducing HIV bnAbs.
EXPERIMENTAL PROCEDURES
Antibodies and Viruses
Antibodies belonging to four V2 apex bnAb prototypes, PG9 (PG9, PG16),
CH01 (CH01-CH04), PGT145 (PGT141, PGT145), CAP256.09 (CAP256.01-
CAP256.12 and CAP256I1-12, CAP256 UCA) were included in this study.
The antibodies have been previously isolated from four individual HIV-1
infected donors (Bonsignori et al., 2011; Doria-Rose et al., 2014; Walker
et al., 2011; Walker et al., 2009). In addition, we used a panel of antibodies
and viruses for different experiments and the details of those are provided in
the Supplemental Experimental Procedures.
Site-Directed Mutagenesis
Amino acid point mutations in HIV envelope and antibody encoding plasmids
were made by using a QuikChange site-directed mutagenesis kit (Stratagene)
according to themanufacturer’s instructions. All themutations were verified by
DNA sequence analysis (Eton Bioscience).
Germline Antibody Design and Antibody Engineering
The variable heavy and light-chain inferred germlines (iGL) of four V2 apex
bnAbs prototypes (PG9, CH01, CAP256.09, and PGT145) were designed ac-
cording to the method described previously (Jardine et al., 2013; Pancera
et al., 2010) (for more details, please refer to Figure 4 and Supplemental Exper-
imental Procedures).
Recombinant Envelope Protein Design
For this study, two envelope sequences (CRF02_AG_250, BG505.Env.C2)
were used to generate soluble gp140 trimeric forms of Env spike trimer
(SOSIP.664 gp140). The env gene sequence of CRF02_AG_250 was retrieved
from GenBank (accession number: EU513189), a subtype AG virus isolated
previously from the peripheral blood mononuclear cells (PBMCs) of an HIV-1
infected donor fromCameroon (isolated by Ellenberger et al., at CDC) (Seaman
et al., 2010). To generate the SOSIP.664 gp140 constructs, we introduced the
changes in the Env sequences as mentioned elsewhere (Sanders et al., 2013).
(See Supplemental Experimental Procedures for more information.)
Expression and Purification of Recombinant Envelope Proteins
For production of trimers with varied glycan composition, the a-mannosidase I
and II inhibitors, kifunensine (Tocris), and swainsonine (Cayman), respectively,
were added to the HEK293F cell cultures at a final concentration of 25 mM
at the time of transfection (Doores and Burton, 2010). CRF02_AG_250
SOSIP.664 gp140 trimer was purified from the supernatants using PGT145
bnAb antibody affinity column as described elsewhere (Sanders et al., 2013).
The BG505.Env.C2 SOSIP.664 gp140 trimer, its glycan variants and gp120
proteins were purified using aGalanthusNivalis Lectin (GNL) (Vector Labs) col-
umn. The affinity-purified proteins were size exclusion chromatography (SEC)
purified with Superdex 200 10-300 GL column (GE Healthcare) in PBS.
Antibody Binding Assay
Enzyme-Linked ImmunoSorbent Assay (ELISA) was performed as described
previously (Sanders et al., 2013). The 50% of maximal binding (EC50) was rep-
resented as the antibody concentrations required to reach half of maximum
binding.IVirus Production and Neutralization Assay
To produce pseudoviruses, we cotransfected plasmids encoding Env with an
Env-deficient backbone plasmid (pSG3DEnv) in a 1:2 ratio with the trans-
fection reagent Fugene 6 (Promega). Kifunensine and swainsonine treated
pseudoviruses were produced by adding these inhibitors to 293T cells at a
final concentration of 25 mM on the day of transfection. Pseudoviruses were
harvested 48–72 hr posttransfection for use in neutralization assays. Neutral-
ization was measured by using single-round-of-infection HIV-1 Env-pseudo-
viruses and TZM-bl target cells, as described previously (Seaman et al.,
2010).
Wong Glycan Microarray
The Abs were assessed for glycan reactivity with amine functional glycans
printed onto NHS-activated glass slides as described previously (Falkowska
et al., 2014) (more details in Supplemental Experimental Procedures).
Autoreactivity Assay
Antibodies were assayed at 100 mg/mL for autoreactivity to HEp-2 cells
(Aesku Diagnostics) by immunofluorescence according to the manufacturer’s
instructions.
Statistical Analysis
Statistical analyses were performed using Graph Pad Prism 6 for Windows,
Graph Pad Software.
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